Get my own profile
Public access
View all173 articles
20 articles
available
not available
Based on funding mandates
Co-authors
Oliver BurtonUniversity of CambridgeVerified email at cam.ac.uk
Michelle LintermanGroup Leader, Babraham InstituteVerified email at babraham.ac.uk
Chris GoodnowGarvan Institute of Medical Research, University of New South Wales SydneyVerified email at garvan.org.au
Isabelle MeytsProfessor, KU LeuvenVerified email at uzleuven.be
Diether LambrechtsLaboratory for Translational Genetics, Department of Oncology, VIB and KULeuven, Leuven, BelgiumVerified email at vib-kuleuven.be
Sylvie LesageProfessor of Immunology, Université de MontréalVerified email at umontreal.ca
Vasiliki LagouAutoimmune Genetics Laboratory, VIB, Leuven 3000, BelgiumVerified email at well.ox.ac.uk
Bart De Stroopergewoon hoogleraar KU Leuven en onderzoeksdirecteur VIBVerified email at cme.vib-kuleuven.be
Kim A. StaatsDirector of Rare Disease Drug Development, INmune BioVerified email at inmunebio.com
Carola G VinuesaThe Francis Crick InstituteVerified email at anu.edu.au
Jeroen RaesProfessor, Faculty of Medicine, Rega Institute, KU Leuven; Group Leader Microbiome, VIB, BelgiumVerified email at med.kuleuven.be
Dina Danso-AbeamSenior Scientist, BD Research Centre IrelandVerified email at legendbiotech.com
Owen SiggsGarvan Institute of Medical ResearchVerified email at garvan.org.au
Li-Fan LuUniversity of California, San DiegoVerified email at ucsd.edu
alexander rudenskymskccVerified email at mskcc.org
Ludo Van Den BoschKU Leuven & VIBVerified email at kuleuven.vib.be
Lydia MakaroffMultiple Sclerosis International FederationVerified email at msif.org
Aikaterini Smaragdi PapadopoulouUniversity College LondonVerified email at ucl.ac.uk
Bernard ThienpontLaboratory of Functional Epigenetics - KULeuven, BelgiumVerified email at kuleuven.be
Peter Carmeliethoogleraar, Universiteit van Leuven, VIBVerified email at kuleuven.vib.be